Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma

Molecular Imaging

Volumn 12, Issue 1, 2013, Pages 67-73

  Stelter, Lars ^c   Evans, Michael J ^a,b   Jungbluth, Achim A ^a,b   Longo, Valerie A ^a,b   Zanzonico, Pat ^a,b   Ritter, Gerd ^a,b   Bomalaski, John S ^a,b   Old, Lloyd ^a,b   Larson, Steven M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Polaris Group   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMORS; ARGININE DEIMINASES; AUXOTROPHY; BLOOD POOL; FLUORESCENCE MOLECULAR TOMOGRAPHY; IMMUNOHISTOCHEMISTRY; L-ARGININE; MELANOMA XENOGRAFTS; MOUSE MODELS; PLASMA LEVELS; SYNTHETASES; TUMOR SIZE; TUMOR VASCULARIZATION; TUMOR VASCULATURE;

ARGININE; BIOLOGICAL MATERIALS; DERMATOLOGY; DRUG PRODUCTS; FLUORESCENCE; NITRIC OXIDE; ONCOLOGY; TOMOGRAPHY;

TUMORS;

ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; HYDROLASE; NITRIC OXIDE;

ANIMAL; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; FEMALE; FLUORESCENCE IMAGING; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TOMOGRAPHY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ARGININOSUCCINATE SYNTHASE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; HYDROLASES; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, SCID; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; OPTICAL IMAGING; TOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84873896084     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2012.00009     Document Type: Article

References (36)

1. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-22, doi:10.1200/JCO.2004.11.120.
2. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-8, doi:10.1200/JCO.2005.02.0933.
3. Yoon CY, Shim YJ, Kim EH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2006;120: 897-905, doi:10.1002/ijc.22322.
4. Kim RH, Coates JM, Bowles TL, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009;69:700-8, doi:10.1158/0008-5472.CAN-08-3157.
5. Bowles TL, Kim R, Galante J, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008;123:1950-5, doi:10.1002/ijc.23723.
6. Kelly MP, Jungbluth AA, Wu BW, et al. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of arginiosuccinate synthetase. Br J Cancer 2012;106:324-32, doi:10.1038/bjc.2011.524.
7. Gonzales GG, Byus CV. Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. Cancer Res 1991;51:2931-9.
8. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers. Cancer 2004;100:826-33, doi:10.1002/cncr.20057.
9. 18F-FDG is not suitable to evaluate response in melanoma. J Nucl Med 2012;53: 281-6, doi:10.2967/jnumed. 111.092973.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47, doi:10.1016/j.ejca. 2008.10.026.
11. Dillon BJ, Holtsberg FW, Ensor CM, et al. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med Sci Monit 2002;8:BR248-53.
12. Ntziachristos V, Schellenberger EA, Ripoll J, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. PNAS 2004;101: 12294-9, doi:10.1073/pnas.0401137101.
13. Ntziachristos V, Tung CH, Bremer C, et al. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002;8: 757-60, doi:10.1038/nm729.
14. Weissleder R, Bogdanov A, Tung CH, et al. Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging. Bioconjug Chem 2001;12:213-9, doi:10.1021/bc000091p.
15. Gilroy E. The influence of arginine upon the growth rate of a transplantable tumour in the mouse. J Biochem 1930;24:589-95.
16. Bach SJ. The effect of arginase on the retardation of tumor growth. Br J Cancer 1967;19:379-84, doi:10.1038/bjc.1965.45.
17. Glazer ES, Piccirillo M, Albino V, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010;28:2220-6, doi:10.1200/JCO.2009. 26.7765.
18. Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM) [abstract]. J Clin Oncol 2009;27 Suppl:15s.
19. Engelmann JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev 2009;9:550-62, doi:10.1038/nrc2664.
20. Xu D, Yao Y, Jiang X, et al. Regulation of PTEN stability and activity by Plk3. J Biol Chem 2010;285:39935-42, doi:10.1074/jbc.M110.166462.
21. Papapetropoulos A, Garcia-Cardena G, Madri JA, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-9, doi:10.1172/JCI119868.
22. Sasaki K, Hattori T, Fujisawa T, et al. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloprotei-nases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem (Tokyo) 1998;123:431-9, doi:10.1093/oxfordjournals.jbchem.a021955.
23. Ambs S, Bennett WP, Merriam WG, et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999;91:86-8, doi: 10.1093/jnci/91.1.86.
24. Park IS, Kang SW, Shin YJ, et al. Arginine deiminase: a potential inhibitor of angiogenesis and tumor growth. Br J Cancer 2003;89: 907-14, doi:10.1038/sj.bjc.6601181.
25. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34, doi:10.1038/nrc1910.
26. Konopka TE, Barker JE, Bamford TL, et al. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 2001;61:3182-7.
27. Callahan RJ, Bogdanov A Jr, Fischman AJ, et al. Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging. AJR Am J Roentgenol 1998; 171:137-43.
28. Ntziachristos V, Ripoll J, Wang L, et al. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 2005;23:313-20, doi:10.1038/nbt1074.
29. Ntziachristos V, Schellenberger E, Ripoll J, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with annexin V-Cy5.5 conjugate. Proc Natl Acad Sci USA 2004;101:12294-9, doi:10.1073/pnas. 0401137101.
30. Montet X, Figueiredo JL, Alencar H, et al. Tomographic fluorescence imaging of tumor vascular volume in mice. Radiology 2007;242:751-8, doi:10.1148/radiol.2423052065.
31. Borutaite V, Morkuniene R, Brown GC. Nitric oxide donors, nitrosothiols and mitochondrial respiration inhibitors induce caspase activatin by different mechanisms. FEBS Lett 2000;467: 155-9, doi:10.1016/S0014-5793(00)01140-6.
32. Borutaite V, Morkuniene R, Arandarcikaite O, et al. Nitric oxide protects the heart from ischemia-induced apoptosis and mito-chondrial damage via protein kinase G mediated blockage of permeability transition and cytochrome c release. J Biomed Sci 2009;16:70, doi:10.1186/1423-0127-16-70.
33. Nielsen CH, Kimura RH, Withofs N, et al. PET imaging of tumor neovascularization in a transgenic mouse model with a novel Cu-64-DOTA-knottin peptide. Cancer Res 2011;70:9022-30, doi: 10.1158/0008-5472.CAN-10-1338.
34. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008;26:4449-57, doi:10.1200/JCO.2007.15.4385.
35. De Langen AJ, Van den Boogaart V, Lubberink M, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 2011;52:48-55, doi:10.2967/jnumed.110.078261.
36. He X, Wang Y, Zhu J, et al. Resveratol enhances the anti-tumor activity if the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signalling. Cancer Lett 2011;301:168-76, doi:10.1016/j.canlet.2010.11. 012.